Compare SXC & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SXC | HQL |
|---|---|---|
| Founded | 1960 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.5M | 512.1M |
| IPO Year | N/A | N/A |
| Metric | SXC | HQL |
|---|---|---|
| Price | $8.05 | $17.23 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 968.9K | 120.9K |
| Earning Date | 01-30-2026 | 01-01-0001 |
| Dividend Yield | 6.11% | ★ 11.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.75 | ★ 0.79 |
| Revenue | ★ $1,843,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | ★ $10.48 | $17.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.24 | $11.34 |
| 52 Week High | $10.20 | $14.37 |
| Indicator | SXC | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 56.69 |
| Support Level | $7.73 | $16.35 |
| Resistance Level | $8.31 | $17.50 |
| Average True Range (ATR) | 0.25 | 0.37 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 68.02 | 75.22 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.